［1］Pernicova I，Korbonits M.Metformin-mode of action and clinical implications for diabetes and cancer［J］.Nat Rev Endocrinol，2014，10(3)：143-156.
［2］Evans JM，Donnelly LA，Emslie-Smith AM，et al.Metformin and reduced risk of cancer in diabetic patients［J］.BMJ，2005，330(7503)：1304-1305.
［3］Lu MZ，Li DY，Wang XF.Effect of metformin use on the risk and prognosis of ovarian cancer：An updated systematic review and meta-analysis［J］.Panminerva Med，2019，18(1)：364-367.
［4］Morales DR，Morris AD.Metformin in cancer treatment and prevention［J］.Annual Review of Medicine，2015，66(1)：17-29.
［5］Chu D，Wu J，Wang K，et al.Effect of metformin use on the risk and prognosis of endometrial cancer：A systematic review and meta-analysis［J］.BMC Cancer，2018，18(1).doi:10.1186/s12885-018-4334-5.
［6］Gandini S，Puntoni M，Heckman-Stoddard BM，et al.Metformin and cancer risk and mortality：A systematic review and meta-analysis taking into account biases and confounders［J］.Cancer Prev Res（Phila)，2014，7(9)：867-885.
［7］Parikh AB，Kozuch P，Rohs N，et al.Metformin as a repurposed therapy in advanced non-small cell lung cancer（NSCLC）：Results of a phase Ⅱ trial［J］.Invest New Drugs，2017(35)：813-819.
［8］Miranda VC，Braghiroli MI，Faria LD，et al.Phase 2 trial of metformin combined with 5-Fluorouracil in patients with refractory metastatic colorectal cance［J］.Clin Colorectal Cancer，2016，15(4)：321-328.
［9］Sivalingam VN，Kitson S，McVey R，et al.Measuring the biological effect of presurgical metformin treatment in endometrialcancer［J］.Br J Cancer，2016，114(3)：281-289.
［10］Martinez JA，Chalasani P，Thomson CA，et al.Phase II study of metformin for reduction of obesity-associated breast cancer risk：A randomized controlled trial protocol［J］.BMC Cancer，2016(16)：500.
［11］Cai D，Sun H，Qi Y，et al.Insulin-like growth factor 1/mammalian target of rapamycin and amp-activated protein kinase signaling involved in the effects of metformin in the human endometrial cancer［J］.Gynecol Cancer，2016，26(9)：1667-1672.
［12］Qian W，Li J，Chen K，et al.Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer［J］.Life Sci，2018，S0024-3205(18)：30432-30436.
［13］Li L，Jiang L.Combination of metformin and gefitinib as first-line therapy for non-diabetic advanced NSCLC patients with EGFR mutations：A randomized，double-blind phase 2 trial［J］.Clin Cancer Res，2019(19)：0437-0439.
［14］Wenxiu X，Xiaowei Z，Haiying D，et al.Impact of metformin use on survival outcomes in non-small cell lung cancer treated with platinum［J］.Medicine，2018，97(51).doi:10.1097/MD.0000000000013652.
［15］Zhang J，Wu J.The prognostic value of metformin for advanced non-small cell lung cancer：A systematic review and meta-analysis［J］.Transl Lung Cancer，2018，7(3)：389-396.
［16］Hirsch HA，Iliopoulos D，Tsichlis PN，et al.Metformin selectively targets cancer stem cells，and acts together with chemotherapy to block tumor growth and prolong remission［J］.Cancer Research，2009，69(19)：7507-7511.
［17］Zhao Z，Cheng X，Wang Y，et al.Metformin Inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis［J］.PLOS ONE，2014:9.
［18］Zhang J，Shen C，Wang L，et al.Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells：Involvement of the tumor suppressor miR30a and its target gene SOX4［J］.Biochemical and Biophysical Research Communications，2014，452(3)：746-752.
［19］Duque JE，Cruz N，Samudio I，et al.Antitumor mechanisms of metformin：Signaling，metabolism，immunity and beyond［J］.Universitas Scientiarum，2010，15(2)：122-129.
［20］Lei Y，Yi Y，Liu Y，et al.Metformin targets multiple signaling pathways in cancer［J］.Chin J Cancer，2017，36(1)：17.
［21］Abo-Elmatty DM，Ahmed EA，Tawfk MK，et al.Increased soluble CD155 in the serum of cancer patients［J］.Plos One，2016，11(4)：e0152982.
［22］Luengo A，Sullivan LB，Heiden MGV.Understanding the complex-I-ty of metformin action：limiting mitochondrial respiration to improve cancer therapy［J］.BMC Biology，2014，12(1)：82.
［23］Levy A，Doyen J.Metformin for non-small cell lung cancer patients：Opportunities and pitfalls［J］.Crit Rev Oncol Hematol，2018(125)：41-47.
［24］Eikawa S，Nishida M，Mizukami S，et al.Immune-mediated antitumor effect by type 2 diabetes drug，metformin［J］.Proc Natl Acad Sci USA，2015，112(6)：1809-1814.
［25］Daugan M，Dufay Wojcicki A，d'Hayer B，et al.Metformin：An anti-di-abetic drug to fight cancer［J］.Pharmacol Res，2016，113(Pt A)：675-685.
［26］Shackelford D，Abt E，Gerken L，et al.LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin［J］.Cancer Cell，2013，23(2)：143-158.
［27］Birsoy K，Possemato R，Lorbeer FK，et al.Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides［J］.Nature，2014，508(7494)：108-112.
［28］Kuo CL，Hsieh Li SM.The antitumor properties of metformin and phenformin reflect their ability to inhibit the actions of differentiated embryo chondrocyte［J］.Cancer Manag，2019，15(11)：6567-6579.
［29］Liu C，Wang F，Fan QX，et al.Advances of clinical trials of metformin in antitumor therapy［J］.Chin J Clin Oncol，2018，45(20)：189-193.
［30］Yang C，Zhao N.Metformin improves the sensitivity of ovarian cancer cells to chemotherapeutic agents［J］.Oncol Lett，2019，18(3)：2404-2411.
［31］Meireles CG，Pereira SA，Valadares LP，et al.Effects of metformin on endometrial cancer：Systematic review and meta-analysis［J］.Gynecol Oncol，2017，147(1)：167-180.